Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Eyes Liver Safety Biomarker As Potential Path To Prexige Approval

Executive Summary

Novartis has identified a genetic sequence that may be a risk factor for serious liver injury in patients receiving Prexige (lumiracoxib), a finding that may signal a development path forward for the COX-2 inhibitor
Advertisement

Related Content

Will COX-2 + Biomarker = Success? Novartis Tests the Frontiers of Companion Diagnostics
Will COX-2 + Biomarker = Success? Novartis Tests the Frontiers of Companion Diagnostics
Serious Adverse Events Consortium Expects Data On Genetic Variants Shortly
Sales of Novartis’ Prexige Suspended in U.K., Germany, Austria After EU Announces Safety Review
No Big Surprise For Novartis: Prexige Is “Not Approvable” At FDA
No Big Surprise For Novartis: Prexige Is “Not Approvable” At FDA
Warfarin Label Change Falls Short of Recommending Genetic Testing
Advertisement
UsernamePublicRestriction

Register

PS050153

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel